Treatment of Dyslipidemia in Diabetes: Recent Advances and Remaining Questions
The DOI matches its Crossref record; 111 of the 113 references it cites were found in a registry or an index.
Abstract
Purpose of review This article reviews current knowledge concerning diabetic dyslipidemia and cardiovascular disease (CVD). It reviews strategies to reduce diabetes-associated CVD, including reducing low-density lipoprotein levels, lowering triglycerides, and increasing high-density lipoproteins (HDL). Special considerations, such as the multifactorial chylomicronemia syndrome and partial lipodystrophy, and the role of glucose-lowering strategies in the management of diabetic dyslipidemia are discussed.Recent findings The strongest evidence to date for reducing CVD in diabetes comes from the use of statins. While triglyceride lowering remains inconclusive, an ongoing trial might provide some finality to this question. The role of increasing HDL remains elusive, and HDL cholesterol appears to be an unsatisfactory metric for monitoring therapy. The use of statins offers the best current way to reduce diabetes-associated CVD. However, several novel and promising approaches for the management of diabetic dyslipidemia aimed at reducing CVD are in the pipeline.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In well-controlled T1DM, HDL-C levels tend to be normal (or even slightly elevated), as are serum TGs.245”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [245]
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Research works printed but not linked: 2
- Purnell JQ, Hokanson JE, Marcovina SM, Cleary PA, Steffes MW, Brunzell JD. Weight gain accompanying intensive diabetes therapy in type 1 diabetes is associated with higher levels of dense LDL cholesterol. JInvestMed. 1996;44:180A.
- Carr MC, Hokanson JE, Zambon A, Deeb SS, Barrett PHR, Purnell JQ, et al. The contribution of intra-abdominal fat to gender differences in hepatic lipase activity and LDL/HDL heterogeneity. J Clin Endo Metab. 2001;86:2831–7.
Cited by
Cosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz486 · Cited by 4,763
2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes.
Marx, N., Federici, M., Schütt, K., Müller-Wieland, D., Ajjan, R. A., Antunes, M. J., Christodorescu, R. M., Crawford, C., Di Angelantonio, E., Eliasson, B., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad192 · Cited by 1,642
Rivera-Mancía, S., Trujillo, J., & Pedraza‐Chaverrí, J. (2018) · Journal of Nutrition & Intermediary Metabolism · doi:10.1016/j.jnim.2018.05.001 · Cited by 101
“This interaction could also be relevant for patients taking curcumin along with other antidiabetic drugs, such as pioglitazone, rosiglitazone, and repaglinide, which inhibit OATP1B1 and OATP1B3 -mediated transport of statins [187,188], given that statins are frequently prescribed for dyslipidemia in diabetes [189].”
BackgroundThe Role of High-Density Lipoproteins in Diabetes and Its Vascular Complications
Wong, N. K. P., Nicholls, S. J., Tan, J. T. M., & Bursill, C. A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061680 · Cited by 81
10-Year Comparative Follow-up of Familial versus Multifactorial Chylomicronemia Syndromes
Belhassen, M., Van Ganse, E., Nolin, M., Bérard, M., Bada, H., Bruckert, E., Krempf, M., Rebours, V., Valero, R., & Moulin, P. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa838 · Cited by 47
Metadata
- Authors
- Chait, A., & Goldberg, I.
- Affiliations
- University of Washington (US)
- New York University (US)
- Corresponding author
- Chait, Alan
- Venue
- Current Diabetes Reports
- Published
- 2017-09-27
- Volume
- 17
- Issue
- 11
- Pages
- 112-112
- ISSN
- 1534-4827 (ISSN-L)
- 1539-0829
- OpenAlex
- W2757879724
- Cited by
- 40
- References
- 113
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 4 · 2023: 4 · 2022: 4 · 2021: 3 · 2020: 8 · 2019: 4 · 2018: 7
- FWCI
- 1.10
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Diabetes Reports (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Heart, Lung, and Blood Institute (P01HL092969)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- diabetic dyslipidemia, cardiovascular disease in diabetes, statins, LDL cholesterol lowering, triglyceride lowering, HDL cholesterol, partial lipodystrophy, glucose-lowering therapy, lipid-lowering therapy
- MeSH terms
- Hypolipidemic Agents, Blood Glucose, Diabetes Mellitus, Humans, Lipids, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Dyslipidemias
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment of Dyslipidemia in Diabetes: Recent Advances and Remaining Questions. https://app.cochat.ai/papers/10.1007/s11892-017-0942-8
- The paper
- Chait, A., & Goldberg, I. (2017). Treatment of Dyslipidemia in Diabetes: Recent Advances and Remaining Questions. Current Diabetes Reports. https://doi.org/10.1007/s11892-017-0942-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.